The Brazilian Federal Prosecutor’s Office has taken court action against Roche for allegedly abusing IP rights in its sales of Herceptin to state governments. Anderson Ribeiro and Ricardo Campello of Provedel Advogados analyse the case.
Following the UK’s vote to leave the EU, it is business as usual for life sciences companies working with intellectual property, at least for now, says Claire Phipps-Jones of Bristows.
Africa Harvest is working towards reducing hunger and poverty in some of the world’s poorest countries. Dr Florence Wambugu, founder of the organisation, tells LSIPR more about its work.
Birmingham—Britain’s second city—with a leading university for research and development, allows biotech companies to enjoy the benefits of a cluster, as James Wilkie, CEO of Alta Innovations, the commercial spinout of the University of Birmingham, told LSIPR.
Owners of second medical use patents may need to think outside the box in terms of the relief they seek for infringement, says Katie Hutchinson of Bristows.
Researchers should keep in mind that broad claims applying the discovery of a biomarker and disease correlation are currently patentable in Europe but not in the US. Andrew Carridge and Neil Thornton of Reddie & Grose report.
Proactively managing patent portfolios is an investment that pays for itself in reduced patent costs. Bruno Reynolds, who works at the consultancy arm of Isis Innovation, the technology transfer company of the University of Oxford, explains more.
Despite its troubled start, Brazil’s Product Development Partnerships programme is now entering a new stage of its development with the introduction of a more complete system for regulation, but there’s also more scope for patent infringement, say Otto Licks and Ricardo Campello of Licks Attorneys.
February’s amendments to the Australian IP Act seek to increase the effectiveness and efficiency of the country’s IP system. LSIPR takes a look at the major changes and considers who will benefit most in the life sciences sector.